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Abstract:  
Background: A number of studies have been conducted in Nigeria on the prevalence of cryptococcal infections mostly 
on HIV-infected patients using culture, India ink and/or latex agglutination tests. These tests are either laborious, 
time-consuming and expensive or have low sensitivity, thus limiting their use. Cryptococcal antigen lateral flow assays 
(LFA) were introduced in the last decade as rapid user-friendly tests for diagnosis. In this study, we sought to 
determine the diagnostic accuracy of an LFA kit for the detection of cryptococcal antigen in the serum of HIV-negative 
patients with or without cerebrovascular accident (CVA) or stroke in University College Hospital, Ibadan, Nigeria. 
Methodology: The diagnostic accuracy of Dynamiker CrAg LFA was tested against BiosynexR CryptoPS on serum 
samples of 100 HIV-negative patients with and without stroke. Samples were tested and results interpreted in 
accordance with the manufacturer’s instructions. The sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (NPV), and positive and negative likelihood ratios of the Dynamiker CrAg LFA were calculated by 
comparing with the BiosynexR CryptoPS as ‘gold standard’.        
Results:  Overall, a total of 98 valid patient sample results were analysed; 17 samples (17.3%) were positive with 
Dynamiker CrAg LFA cryptococcal antigen and 16 samples (16.3%) were positive with BiosynexR CryptoPS. The 
sensitivity, specificity, PPV and NPV of Dynamiker CrAg LFA compared to the BiosynexR CryptoPS were 100%, 98.8%, 
94.1% and 100% respectively, while the positive and negative likelihood ratios were 82 and 0 respectively. 
Conclusion: In comparison to the BiosynexR CryptoPS, the Dynamiker CrAg LFA is a highly sensitive and specific test 
for the detection of cryptococcal antigen in serum. The test kit should be considered as a screening device for 
cryptococcal infection both in outreach and clinical settings, especially in antiretroviral therapy (ART) centres. 
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Abstrait: 
Contexte: Un certain nombre d'études ont été menées au Nigéria sur la prévalence des infections à cryptocoques 
principalement chez les patients infectés par le VIH en utilisant des tests d'agglutination en culture, à l'encre de Chine 
et / ou au latex. Ces tests sont soit laborieux, longs et coûteux ou ont une faible sensibilité, limitant ainsi leur 
utilisation. Les tests d'écoulement latéral de l'antigène cryptococcique (LFA) ont été introduits au cours de la dernière 
décennie en tant que tests conviviaux rapides pour le diagnostic. Dans cette étude, nous avons cherché à déterminer 
la précision diagnostique d'un kit LFA pour la détection de l'antigène cryptococcique dans le sérum de patients 
séronégatifs avec ou sans accident vasculaire cérébral (AVC) ou accident vasculaire cérébral à University College 
Hospital, Ibadan, Nigeria.                                      
Méthodologie: La précision diagnostique de Dynamiker CrAg LFA a été testée contre BiosynexR CryptoPS sur des 
échantillons de sérum de 100 patients séronégatifs avec et sans accident vasculaire cérébral. Les échantillons ont été 
testés et les résultats interprétés conformément aux instructions du fabricant. La sensibilité, la spécificité, la valeur 
prédictive positive (PPV), la valeur prédictive négative (NPV) et les rapports de vraisemblance positifs et négatifs du 
Dynamiker CrAg LFA ont été calculés en les comparant avec le BiosynexR CryptoPS comme ‘gold standard’.  
Résultats: Au total, 98 résultats d'échantillons de patients valides ont été analysés; 17 échantillons (17,3%) étaient 
positifs avec l'antigène cryptococcique Dynamiker CrAg LFA et 16 échantillons (16,3%) étaient positifs avec BiosynexR 
CryptoPS. La sensibilité, la spécificité, le PPV et le NPV de Dynamiker LFA par rapport au BiosynexR CryptoPS étaient 
respectivement de 100%, 98,8%, 94,1% et 100%, tandis que les rapports de vraisemblance positifs et négatifs 
étaient respectivement de 82 et 0.                                                                
Conclusion: Par rapport au BiosynexR CryptoPS, le Dynamiker CrAg LFA est un test hautement sensible et spécifique 
pour la détection de l'antigène cryptococcique dans le sérum. Le kit de test doit être considéré comme un dispositif 
de dépistage de l'infection cryptococcique à la fois dans les milieux de proximité et cliniques, en particulier dans les 
centres de thérapie antirétrovirale (ART). 
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Introduction: 
 Cryptococcosis is a systemic fungal 
infection caused by Cryptococcus neoformans 
and Cryptococcus gatti complex (1). These fungi 
are considered potential pathogenic species and 
infect both human and animal hosts. While it is 
indeed true that C. neoformans infections are 
commoner among the immunocompromised, C. 
gatti, on the other hand is more frequently 
implicated in fungal infections among immuno- 
competent hosts. The commonest infections 
they cause in humans include meningitis, 
pneumonia and disseminated cryptococcosis, 
mostly in immunosuppressed hosts. Sporadic 
cases of these infections are reported all over 
the world. However, in recent times, the AIDS 
pandemic has been the significant factor for 
increased incidence of this disease. Cryptococcal 
meningitis is one of the common causes of 
unconsciousness and adult meningitis in Africa, 
(2) resulting in about 20-25% of AIDS-related 
deaths (3,4).     
 Although, the major risk factors for 
cerebrovascular accident (CVA) or stroke in the 
Nigerian population include hypertension, 
alcohol consumption, sedentary lifestyle, and 
impaired glucose tolerance, these factors do not 
entirely explain the occurrence of stroke. 
Meanwhile, patients with uncontrolled hyper- 
tension who usually suffer stroke present at the 
hospital in coma in the Nigerian setting. Coma, 
being a common presentation of both crypto- 
coccal meningitis and stroke, may thus present 
a diagnostic challenge, necessitating a rapid 
screening to exclude cryptococcal infection (5). 
 Laboratory diagnosis of cryptococcal 
infections have traditionally been carried out by 
CSF culture for isolation of the pathogen, India 
ink test and/or cryptococcal antigen latex 
agglutination tests. However, these tests are 
either laborious, time-consuming, expensive or 
have low sensitivity, thus limiting their clinical 
use. For instance, the ‘gold standard’ test for the 
diagnosis of cryptococcal meningitis is CSF 
culture but diagnosis by culture can take up to 
1 or 2 weeks for definitive results. India ink test, 
though quick, has a low sensitivity resulting in 
missed infections (6). Thus, other test methods 
have been devised to expedite diagnosis and 
treatment, thus improving clinical outcome.  
 The cryptococcal antigen lateral flow 
assay (LFA) tests were introduced in the last 
decade of this century as rapid user-friendly 
tests for diagnosis of Cryptococcus infections. 
The use of these assays has simplified the 
presumptive diagnosis of cryptococcal infection 
as point-of-care test using serum/plasma, whole 
blood and cerebrospinal fluid (CSF). The LFA 
have been reported to demonstrate high accuracy  




in these body fluids for the diagnosis of 
cryptococcosis in patients at risk of infection (7). 
 The first of these kits was manufactured 
by IMMY and has been validated and licensed for 
use in many countries. Other LFA kits such as 
the BiosynexR CryptoPS have been found to also 
perform well (6,8,9), with comparable diag- 
nostic accuracy to the IMMY CrAg kit that is 
considered the ‘gold standard’ LFA test on serum 
samples (8). Furthermore, other newer test kits 
have been manufactured and are in need of 
evaluation. We therefore evaluated the diag- 
nostic accuracy of the Dynamiker CrAg LFA test 
against BiosynexR CryptoPS using sera of HIV-
negative patients with and without stroke in 
Ibadan, southwest Nigeria.  
Materials and method:  
Study setting     
 The study was conducted in Ibadan, 
southwestern Nigeria as part of the Stroke 
Investigative Research and Education Network 
(SIREN) project, a multicentre and multi- 
disciplinary study on stroke in sub-Saharan 
Africa.  
Study design, subjects and sample collection 
 This was a comparative evaluation study 
of the diagnostic accuracy of the cryptococcal 
CrAg LFA (Dynamiker Biotechnology, Tianjin 
Co., Ltd,) against BiosynexR CryptoPS kits on 
sera of 100 HIV-negative adult patients aged 
≥18 years with and without stroke, randomly 
selected from the SIREN project.  
 Approximately 5ml of venous blood 
samples were collected from each patient. Blood 
samples were allowed to clot and serum was 
separated by centrifugation and stored at -80oC 
until use. The study was approved by the 
University of Ibadan/University College Hospital 
Ethics Review Committee. 
Sample testing by the lateral flow assay kits  
 The serum samples were allowed to 
thaw for at least one hour at room temperature, 
and then tested against the Dynamiker CrAg 
(LOT 17040) and BiosynexR CryptoPS kits 
strictly in accordance with the manufacturer’s 
instructions.   
Principle of the lateral flow device  
 Both test kits use the lateral flow 
technique and double antibody sandwich format. 
In the kit, the test cassette consists of 
Cryptococcus antibodies bound to gold particles 
and coated on fibre glass. The cassette has a 
test line (T) and a control line (C) on 
nitrocellulose membrane which are coated with 
Cryptococcus and goat anti-mouse antibodies 
respectively. The cryptococcal antigens if pre- 
sent in the test samples form antigen-antibody 
complexes with the gold-conjugated antibodies 
and migrate further along the nitrocellulose 
membrane. The antibodies immobilized on the 
test line (T) interact with the above complexes 
causing a visible red line. The wicking of samples 
causes free gold-conjugated antibodies to reach 
the control line (C) to form red colour. The 
absence of cryptococcal antigens in negative 
samples only cause a colour change in the 
control line (C), which is essentially a quality 
control measure to ensure the test is visually 
validated to be functioning properly. 
Procedural steps    
 Following strictly the instructions of the 
manufacturer for the Dynamiker CrAg LFA, the 
test kit was removed from the pouch and placed 
on a flat surface. 80μL of the serum sample was 
gently dispensed onto the sample pad and result 
read within 15-20 minutes, and interpreted as 
positive, negative or invalid. Where interpre- 
tation was difficult due to high viscosity of serum 
sample, such sample was re-centrifuged and the 
test repeated.     
 For the BiosynexR CryptoPS, the test kit 
was similarly removed from the pouch and 
placed on a flat, horizontal surface. 20μL of the 
serum sample was dispensed into the well, 
followed by 3 drops of the diluent. Result was 
read and interpreted as positive, negative or 
invalid in accordance with the manufacturer’s 
instructions. 
Data analysis     
 The sensitivity, specificity, positive and 
negative predictive values of the Dynamiker 
CrAg test were calculated in reference to the 
BiosynexR CryptoPS using the formula; sensi- 
tivity=TP/TP+FN x (100), specificity=TN/TN+FP 
x(100), PPV=TP/TP+FP x (100) and NPV=TN/ 
TN+FN x (100), where TP=True Positive, TN= 
True Negative, FP=False Positive and FN=False 
Negative. The positive likelihood ratio (PLR) and 
negative likelihood ratio (NLR) were also com- 
puted as follows; NLR=(1-sensitivity)/specifi- 
city and PLR=sensitivity/(1-specificity).  
Results:  
 A total of 100 serum samples from 100 
HIV-negative patients with or without stroke 
were tested by both the Dynamiker CrAg LFA 
and BiosynexR CryptoPS kits. After the initial 
test, 12 samples produced invalid results for the 
two kits but on repeat testing, only 2 samples 
remained invalid. A total of 98 sample results 
were therefore analysed. Seventeen samples 




(17.3%) were positive for Dynamiker CrAg LFA 
while 16 (16.3%) were positive for BiosynexR 
CryptoPS assay (Table 1). The sensitivity, 
specificity, PPV and NPV of Dynamiker CrAg LFA 
compared to the ‘gold standard’ BiosynexR 
CryptoPS were 100%, 98.8%, 94.1% and 100% 
respectively. The positive and negative likeli- 
hood ratios were respectively 82 and 0 (Table 2).   
Table 1: Cryptococcal antigen testing using Dynamiker CrAg LFA and 
BiosynexR CryptoPS assay kits 
Diagnostic kit BiosynexR CryptoPS 
Positive Negative Total 
Dynamiker CrAg LFA 
Positive 16 1 17 
Negative 0 81 81 
Total 16 82 98 
Sensitivity of Dynamiker CRAG LFA=16/16 (100%); Specificity=81/82 (98.8%);                                                    
Negative Predictive Value (NPV)=81/81 (100%); Positive Predictive Value 
(PPV)=16/17 (94.1%); Negative Likelihood Ratio = 0.0; Positive Likelihood Ratio = 
82.0; Disease Prevalence = 16.3%. 
Table 2: Summary of the diagnostic performance of Dynamiker CrAg 
LFA compared to the ‘gold standard’ 
Characteristics Sensitivity  Specificity  NPV PPV 
Value (%) 100 98.8 100 94.1 




NPV=Negative Predictive Value; PPV=Positive Predictive Value; CI=Confidence 
Interval  
Discussion: 
 In this study, the Dynamiker CrAg LFA 
was highly sensitive and specific in detecting 
cryptococcal antigen in the serum of HIV-
negative patients with and without stroke when 
compared to BiosynexR CryptoPS. The negative 
predictive value was 100% while the positive 
predictive value was 94.1%. These results imply 
that the probability of cryptococcal disease not 
being present when the test is negative is 100%, 
while the probability that the disease is present 
when the test is positive is 94.1%. The positive 
likelihood ratio was greater than 20 while the 
negative likelihood ratio was less than 0.1, 
which proved that ill people with cryptococcal 
infection are more likely to have abnormal test 
results compared to healthy people.   
 The Dynamiker CrAg test was simple to 
use and rapid in detecting cryptococcal antigen 
in the serum samples of the patients. The test 
requires minimal training or equipment and 
therefore should be considered as a screening 
device both in outreach and clinical setting 
especially in ART centres.   
 Our study was limited by the inability to 
perform this evaluation with the more preferred 
IMMY CrAg test that is considered to be the LFA 
‘gold standard’ test for detecting cryptococcus 
infection. This limitation was however compen- 
sated for by the use of the BiosynexR CryptoPS 
kit which has been reported to have comparable 
diagnostic accuracy with IMMY CrAg test and is 
CE-marked for use in Europe (8).  
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